Lunai Bioworks (LNAI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special Meeting scheduled for August 15, 2025, to be held virtually for all shareholders.
Main agenda: approval of a reverse stock split and potential adjournment to solicit more proxies.
Reverse split aims to maintain Nasdaq listing by increasing share price above $1.00.
Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve a reverse stock split at a ratio between 1-for-3 and 1-for-10, at Board's discretion.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies.
Both proposals are considered routine matters; brokers may vote without instructions.
No appraisal or dissenter's rights are available for these proposals.
Board of directors and corporate governance
Board has sole discretion to determine the final split ratio and whether to implement or abandon the reverse split.
Board recommends a vote FOR both the reverse split and adjournment proposals.
Board may call special meetings and appoint proxies for voting.
Latest events from Lunai Bioworks
- Patented AI platform delivers de-risked CNS and oncology assets, driving pharma partnerships.LNAI
Investor presentation17 Feb 2026 - Returned to profitability with $1.0M net income, but faces funding and delisting risks.LNAI
Q2 202617 Feb 2026 - Shelf registration enables up to $200M in offerings to fund biotech and AI-driven cancer initiatives.LNAI
Registration Filing16 Dec 2025 - Shareholders will vote on directors, compensation, auditor, and equity plan amendments at the annual meeting.LNAI
Proxy Filing2 Dec 2025 - Virtual vote set for reverse stock split to maintain Nasdaq listing; Board urges approval.LNAI
Proxy Filing2 Dec 2025 - Q3 2025 net income of $2.8M marks a turnaround, but funding and going concern risks persist.LNAI
Q1 202614 Nov 2025 - Net loss surged to $178M on heavy goodwill impairment, with urgent need for new funding.LNAI
Q4 202529 Sep 2025 - Net loss doubled to $80.7M as Renovaro pivots to AI diagnostics amid funding and legal risks.LNAI
Q4 202413 Jun 2025 - Net loss narrowed sharply on lower impairments, but going concern risks persist amid funding needs.LNAI
Q3 20256 Jun 2025